First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

BACKGROUND: Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in the TASCO1 trial; here, we present the final overall surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Cutsem, E., Danielewicz, I., Saunders, M. P., Pfeiffer, P., Argilés, G., Borg, C., Glynne-Jones, R., Punt, C. J. A., Van de Wouw, A. J., Fedyanin, M., Stroyakovskiy, D., Kroening, H., Garcia-Alfonso, P., Wasan, H., Falcone, A., Fougeray, R., Egorov, A., Amellal, N., Moiseyenko, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130487/
https://www.ncbi.nlm.nih.gov/pubmed/35440667
http://dx.doi.org/10.1038/s41416-022-01737-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130487/
https://www.ncbi.nlm.nih.gov/pubmed/35440667
http://dx.doi.org/10.1038/s41416-022-01737-2

Ejemplares similares